Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus STAVUDINE LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus STAVUDINE LAMIVUDINE.
EMTRIVA vs STAVUDINE; LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with natural substrate thymidine triphosphate and causing chain termination after incorporation. Lamivudine is also an NRTI that inhibits HIV-1 reverse transcriptase via similar competition and chain termination.
Emtricitabine 200 mg orally once daily.
Stavudine 30 mg plus lamivudine 150 mg orally twice daily. For weight <60 kg: stavudine 30 mg twice daily; for weight ≥60 kg: stavudine 40 mg twice daily (but fixed-dose combination typically uses 30 mg).
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Stavudine: 1.5-2 h (adults) but intracellular active triphosphate t1/2 3.5-6 h; Lamivudine: 5-7 h (adults) with intracellular triphosphate t1/2 10.5-15.5 h. Renal impairment prolongs elimination; dose adjustment needed for CrCl <50 mL/min.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Stavudine: 40% renal (unchanged) via glomerular filtration and tubular secretion. Lamivudine: 70% renal (unchanged) via glomerular filtration and tubular secretion. Both: minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antiretroviral, NRTI
NRTI